# Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults

> **NCT01046539** · PHASE1 · COMPLETED · sponsor: **National Institute on Drug Abuse (NIDA)** · enrollment: 12 (estimated)

## Conditions studied

- Substance-Related Disorders

## Interventions

- **DRUG:** RDC-0313 + Buprenorphine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01046539
- **Lead sponsor:** National Institute on Drug Abuse (NIDA)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-03
- **Final completion:** 2010-07
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2017-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01046539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01046539, "Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01046539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*